ObesityNCT07280221
WEgovy Real World Assessment of Weight Loss in Korea
An observational study of Obesity, run by Novo Nordisk A/S at 18 sites in South Korea.
Trial summary
This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Obesity
- What is being tested?
- Semaglutide
- Type of treatment
- Injection or infusion
- How many people
- 500 participants
- Where
- 18 sitesSouth Korea
- Study dates
- 10 Nov 2025to 31 Oct 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.
Who may be able to join
- Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study.
- Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label.
- Male or female, aged ≥ 19 years at the time of signing the informed consent.
Who cannot join
- Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study.
- Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice).
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.
Trial locations and contacts
18 sites in 1 country. Contact the study team or a site near you to ask about taking part.
18 sites in 1 country
South Korea18 sites
Inje University Haeundae Paik Hospital
Busan, 48108
Dong-A University Hospital
Busan, 49201
Keimyung University Dongsan Hospital
Daegu, 42601
Daejeon Endo Internal Medicine Clinic
Daejeon, 35220
Konyang University Hospital
Daejeon, 35365
National Health Insurance Corporation Ilsan Hospital
Goyang-si, Gyeonggi-do, 10444
Chung-Ang University Gwangmyeong Hospital
Gwangmyeong-si, Gyeonggi-do, 14353
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, 13496
Seoul Happiness Clinic of internal medicine
Seongnam-si, Gyeonggi-do, 13612
Chung-Ang University Hospital
Seoul, 06973
Ewha Womans University Seoul Hospital
Seoul, 07804
Korea University Guro Hospital
Seoul, 08308
Ajou University Hospital
Suwon, Gyeonggi-do, 16499
The Catholic University of Korea. Uijeongbu St. Mary's Hospital
Uijeongbu-si, Gyeonggi-do, 11765
Uijeongbu Eulji university Hospital
Uijeongbu-si, Gyeonggi-do, 11759
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, 50612
Yongin Severance Hospital
Yongin-si, 16995
About this study
Official title: WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea
This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.
- Conditions
- Obesity
- Being tested
- Semaglutide
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SemaglutideDrug
Semaglutide injection will be self-administered once weekly subcutaneously.
| Study group | Role | What they receive |
|---|---|---|
| Once weekly Wegovy | Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study. Receives: Drug: Semaglutide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage change in body weight
Percent (%)
Measured: From baseline (week 0) to 24 weeks
Secondary outcomes (29)
Absolute change in body weight
Kilogram (kg)
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Percentage change in body weight
Percent (%)
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction more than or equal to (≥) 5%
Count of patients
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 10%
Count of patients
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 15%
Count of patients
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 20%
Count of patients
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Lean body mass
Kg
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Total fat mass
Kg
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Lean body mass
Percent (%)
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Total fat mass
Percent (%)
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in Body mass index (BMI)
Kilogram per meter square (kg/m^2)
Measured: From baseline (week 0) up to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class I obesity (25 to 29.9 kg/m^2)
Count of patients
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class II obesity (30 to 34.9 kg/m^2)
Count of patients
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class III obesity (≥35 kg/m^2)
Count of patients
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in waist circumference
Centimetre (cm)
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Systolic blood pressure (SBP)
Millimetres of mercury (mmHg)
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Diastolic blood pressure (DBP)
mmHg
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Fasting plasma glucose (FPG)
Milligram per deciliter (mg/dL)
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Haemoglobin A1c (HbA1c)
Percent (%)
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: total cholesterol (TCh)
mg/dL
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: high-density lipoprotein cholesterol (HDL-C)
mg/dL
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: low-density lipoprotein cholesterol (LDL-C)
mg/dL
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: triglycerides (TG)
mg/dL
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: free fatty acid (FFA)
mg/dL
Measured: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in status of type two diabetes mellitus (T2DM)
Count of patients
Measured: Baseline (week 0) to 52 weeks [or end of the study (EOS)]
Change in status of Hypertension
Count of patients
Measured: Baseline (week 0) to 52 weeks (or EOS)
Change in status of Dyslipidemia
Count of patients
Measured: Baseline (week 0) to 52 weeks (or EOS)
Number of treatment-emergent adverse events (TEAEs)
Count of events
Measured: From baseline (week 0) to 52 weeks (or EOS)
Number of serious TEAEs
Count of events
Measured: From baseline (week 0) to 52 weeks (or EOS)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Dec 2025
- Study start10 Nov 2025
- Primary completion31 Oct 2027 (estimated)
- Study completion31 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Transparency dept. 2834, Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07280221
- Sponsor's protocol ID
- NN9536-7850
- Other IDs
- U1111-1306-1595
- Status last verified
- Sep 2026
- First submitted
- 24 Nov 2025
- Last updated
- 30 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- WEgovy Real World Assessment of Weight Loss in Korea (WE-WALK): a Multi-centre, Prospective, Single-arm, Nonintervention Study to Investigate the Effectiveness and Safety of Once-weekly Semaglutide 2.4 mg for People Living With Obesity in Routine Clinical Practice in Korea
- ClinicalTrials.gov ID
- NCT07280221
- Acronym / sponsor ID
- NN9536-7850
- Conditions
- Obesity
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- 10 Nov 2025 (actual)
- Primary completion
- 31 Oct 2027 (estimated)
- Study completion
- 31 Oct 2027 (estimated)
- First posted
- 12 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Once weekly Wegovy | – | Drug: SemaglutideParticipants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study. |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.
Key inclusion criteria (4 listed)
- Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- The decision to initiate treatment with commercially available Wegovy (semaglutide) has been made by the patient and the treating physician before and independently from the decision to include the patient in this study.
- Initiating treatment with Wegovy (semaglutide) for the first time and according to locally approved label.
- Male or female, aged ≥ 19 years at the time of signing the informed consent.
Key exclusion criteria (3 listed)
- Previous participation in clinical studies including treatment with Wegovy (semaglutide). Participation is defined as providing informed consent in a previous study.
- Female patient who is pregnant, breast-feeding, or intends to become pregnant and is of childbearing potential not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice).
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SemaglutideSemaglutide injection will be self-administered once weekly subcutaneously. | Drug | Once weekly Wegovy |
Primary outcome
Percentage change in body weight
Time frame: From baseline (week 0) to 24 weeks
Percent (%)
29 secondary outcomes
Absolute change in body weight
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Percentage change in body weight
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction more than or equal to (≥) 5%
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 10%
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 15%
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 20%
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Lean body mass
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Total fat mass
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Lean body mass
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Total fat mass
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in Body mass index (BMI)
Time frame: From baseline (week 0) up to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class I obesity (25 to 29.9 kg/m^2)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class II obesity (30 to 34.9 kg/m^2)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class III obesity (≥35 kg/m^2)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in waist circumference
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Systolic blood pressure (SBP)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Diastolic blood pressure (DBP)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Fasting plasma glucose (FPG)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Haemoglobin A1c (HbA1c)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: total cholesterol (TCh)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: high-density lipoprotein cholesterol (HDL-C)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: low-density lipoprotein cholesterol (LDL-C)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: triglycerides (TG)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: free fatty acid (FFA)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in status of type two diabetes mellitus (T2DM)
Time frame: Baseline (week 0) to 52 weeks [or end of the study (EOS)]
Change in status of Hypertension
Time frame: Baseline (week 0) to 52 weeks (or EOS)
Change in status of Dyslipidemia
Time frame: Baseline (week 0) to 52 weeks (or EOS)
Number of treatment-emergent adverse events (TEAEs)
Time frame: From baseline (week 0) to 52 weeks (or EOS)
Number of serious TEAEs
Time frame: From baseline (week 0) to 52 weeks (or EOS)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2026.
- Individual participant dataSharing planned: Yes. According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Clinical Transparency dept. 2834 study director
Novo Nordisk A/S
18 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity, run by Novo Nordisk A/S at 18 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 30 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 18 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage change in body weight (time frame: From baseline (week 0) to 24 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2026.